Belgium· BE-AMP-SAM664335-00
Lynozyfic 200 mg
A medicinal product containing linvoseltamab, registered in Belgium by Regeneron Ireland Designated Activity Company (DAC).
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Linvoseltamab
- Manufacturer
- Regeneron Ireland Designated Activity Company (DAC)
- Country
- Belgium (BE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linvoseltamab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLYNOZYFICRegeneron Ireland Designated Activity Company, Dublin
- FinlandLYNOZYFICRegeneron Ireland Designated Activity Company (DAC)
- IrelandLYNOZYFIC 200 mg concentrate for solution for infusionRegeneron Ireland Designated Activity Company
- IcelandLynozyficRegeneron Ireland Designated Activity Company
- SwedenLYNOZYFIC 200 mg Koncentrat till infusionsvätska, lösningRegeneron Ireland Designated Activity Company
- United StatesLYNOZYFICRegeneron Pharmaceuticals, Inc.
- SpainLYNOZYFIC 200 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- NetherlandsLYNOZYFIC 200 mg concentraat voor oplossing voor infusieRegeneron Ireland Designated Activity Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lynozyfic
- Liechtenstein · Lynozyfic
- Norway · Lynozyfic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f96c1770-31aa-4f73-82cb-02f7df674ee1 GET /v1/drugs/f96c1770-31aa-4f73-82cb-02f7df674ee1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Lynozyfic 200 mg",
"name_fr": "Lynozyfic 200 mg",
"name_nl": "Lynozyfic 200 mg",
"amp_code": "SAM664335-00",
"strengths": [
"20.0000",
"20.0000",
"1.0000"
],
"pack_count": 1,
"substances": [
"Linvoseltamab",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": null,
"authorisation_numbers": [
"EU/1/25/1917/002"
]
}See everything about linvoseltamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.